Literature DB >> 16154623

Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence.

M Arbyn1, E Paraskevaidis, P Martin-Hirsch, W Prendiville, J Dillner.   

Abstract

OBJECTIVE: Human papilloma virus (HPV) testing and repeat cytology are both proposed as methods to triage women with minor cytological cervical lesions. By triage, those women can be identified who need referral for diagnostic exploration with colposcopy and/or biopsy.
METHODS: We conducted meta-analyses of reported studies on the accuracy to detect high-grade cervical intra-epithelial neoplasia or worse disease (CIN2+) in women with ASCUS or LSIL. We also performed meta-analyses to examine the best predictor of recurrence of CIN after treatment for CIN2 or CIN3.
RESULTS: We found that HPV testing using the Hybrid Capture II test is more effective (more sensitive, equally specific) than cytology for the triage of patients with ASCUS Pap smears. Because of the high rate of HPV positivity, this is not the case for patients with LSIL. Studies concerning post-treatment follow-up were heterogeneous. In general, HPV testing performed better than follow-up cytology to predict success or failure of treatment (significantly higher sensitivity, not significantly lower specificity).
CONCLUSIONS: Overall, in comparison with follow-up cytology, HPV DNA testing is more sensitive and equally specific for triage of ASCUS cases and for predicting recurrence of CIN in women treated for high-grade CIN.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16154623     DOI: 10.1016/j.ygyno.2005.07.033

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  42 in total

1.  Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix.

Authors:  Simon Grandjean Lapierre; Philippe Sauthier; Marie-Hélène Mayrand; Simon Dufresne; Patrick Petignat; Diane Provencher; Pierre Drouin; Philippe Gauthier; Marie-Josée Dupuis; Bertrand Michon; Stéphan Ouellet; Rachid Hadjeres; Alex Ferenczy; Eduardo L Franco; François Coutlée
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

Review 2.  Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Authors:  Vikrant V Sahasrabuddhe; Patricia Luhn; Nicolas Wentzensen
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

3.  When to test women for human papillomavirus.

Authors:  Mark Schiffman; Philip E Castle
Journal:  BMJ       Date:  2006-01-14

4.  Cervical intraepithelial neoplasia and higher long term risk of cancer.

Authors:  Guglielmo Ronco; Mario Giovanni Sideri; Stefano Ciatto
Journal:  BMJ       Date:  2007-10-24

5.  Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer.

Authors:  Philip E Castle; Ana C Rodríguez; Robert D Burk; Rolando Herrero; Allan Hildesheim; Diane Solomon; Mark E Sherman; Jose Jeronimo; Mario Alfaro; Jorge Morales; Diego Guillén; Martha L Hutchinson; Sholom Wacholder; Mark Schiffman
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

6.  Diagnostic value of MCM2 immunocytochemical staining in cervical lesions and its relationship with HPV infection.

Authors:  Jian Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 7.  How to evaluate emerging technologies in cervical cancer screening?

Authors:  Marc Arbyn; Guglielmo Ronco; Jack Cuzick; Nicolas Wentzensen; Philip E Castle
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

8.  Agreement for HPV genotyping detection between self-collected specimens on a FTA cartridge and clinician-collected specimens.

Authors:  Yaoyao Guan; Patti E Gravitt; Roslyn Howard; Yolanda J Eby; Shaoming Wang; Belinda Li; Changyan Feng; You-Lin Qiao; Philip E Castle
Journal:  J Virol Methods       Date:  2013-01-29       Impact factor: 2.014

9.  Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Authors:  Luisa Barzon; Colomba Giorgi; Franco M Buonaguro; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2008-12-16       Impact factor: 2.965

10.  Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions.

Authors:  S Brismar-Wendel; M Froberg; A Hjerpe; S Andersson; B Johansson
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.